0001104659-22-076722.txt : 20220701 0001104659-22-076722.hdr.sgml : 20220701 20220701132320 ACCESSION NUMBER: 0001104659-22-076722 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220629 FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HEALY JAMES CENTRAL INDEX KEY: 0001245624 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 221060646 MAIL ADDRESS: STREET 1: 3000 SAND HILL ROAD, 4-250 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 tm2220245-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-06-29 0 0001771917 Karuna Therapeutics, Inc. KRTX 0001245624 HEALY JAMES SOFINNOVA INVESTMENTS, INC., 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 1 0 0 0 Common Stock 683 I By Sofinnova Synergy Master Fund, LP Common Stock 2022-06-29 4 P 0 27777 121.99 A 1980218 I By Sofinnova Venture Partners X, LP Common Stock 2022-06-29 4 P 0 4039 122.95 A 1984257 I By Sofinnova Venture Partners X, LP Common Stock 2022-06-29 4 P 0 6832 124.73 A 1991089 I By Sofinnova Venture Partners X, LP Common Stock 2022-06-29 4 P 0 9129 125.00 A 2000218 I By Sofinnova Venture Partners X, LP Common Stock 2022-06-30 4 P 0 48062 122.27 A 2048280 I By Sofinnova Venture Partners X, LP Common Stock 2022-06-30 4 P 0 24161 123.39 A 2072441 I By Sofinnova Venture Partners X, LP All shares held by Sofinnova Synergy Master Fund, LP (the "Fund"). Sofinnova Synergy Fund GP, LLC (the "GP"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $121.50 to $122.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (2) to this Form 4. All shares held by Sofinnova Venture Partners X, LP ("SVP X"). Sofinnova Management X, LLC (the "SM X"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.755 to $123.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $124.00 to $124.99, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.145 to $122.962, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $123.21 to $123.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (7) to this Form 4. /s/ Nathalie Auber, Attorney-in-Fact 2022-06-30